Adjacent Evidence Brief: Sulforaphane NRF2

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Reconcile the Evidence Landscape with the source_bundle: either include all 21 admitted sources in the outcome-class summaries or explicitly state in each packet which sources were routed to 'adjacent context' vs 'direct outcome' and which were excluded from the packets entirely.
2. Reclassify Brown 2015, Duran 2016, Doss 2016, Wise 2016, and Mitra 2016 in the Evidence Landscape with correct directness tiers (these are human interventional studies, not 'indirect' or 'review' sources), and update the abstract claim that there is 'no direct interventional hard-endpoint evidence' accordingly, or explicitly define 'hard-endpoint' to exclude these (e.g., patient-relevant clinical outcomes vs biomarker endpoints).
3. Redefine the 'Strongest signal' column to distinguish surrogate/mechanistic significance from clinical hard-endpoint significance, so readers cannot conflate a significant p-value from a rodent model with a significant clinical effect.
4. Enumerate the 5 cross-study disagreements explicitly in the Gaps section to make the audit trail complete.
5. Provide a short Key Findings paragraph (3–5 bullets) summarizing the actual outcome-class signals rather than restating the outcome-class note.

Major issues

• The Evidence Landscape tables and narrative list only 4 outcome-class packets but the Research Question and Key Findings report 21 included source papers and 902 claims across the corpus. Several sources in the source_bundle (Clifford 2021, Doss 2016, Wise 2016, OMealey 2016, Mohammad 2022, Fu 2026, Xie 2025, Mitra 2026) are not represented in the outcome-class summaries, creating an audit gap between the cited bundle and the evidence landscape tables.
• The abstract states 'no direct interventional hard-endpoint evidence' but Brown 2015 is a human intervention trial (n=45, sulforaphane 100 μmol daily for 14 days with measured bronchoprotection endpoints) and Duran 2016, Doss 2016, Wise 2016, and Mitra 2026 are also human intervention studies. These are direct human interventional evidence and should be reclassified rather than labeled as 'no direct interventional hard-endpoint evidence.'
• The 'Strongest signal' column reports 'significant source statistic in X/N sources' but most reported p-values are from surrogate, mechanistic, or preclinical endpoints, yet the column header and narrative frame this as if it were a clinical efficacy signal. The distinction between 'significant surrogate/mechanistic statistic' and 'significant clinical hard-endpoint statistic' is collapsed.

Minor issues

• The Key Findings section is essentially a repeated outcome-class note rather than a synthesized set of findings; it does not enumerate the actual key findings.
• The Gaps section references '5 disagreement(s)' but the abstract also says '5 cross-study disagreements' without specifying which disagreements, limiting auditability.
• The Conclusion is appropriately bounded but somewhat repetitive across paragraphs; bounded redundancy is acceptable but tightening would improve readability.
• Several author-year citations in the Evidence Landscape (Brown 2015, Bose 2020, Duran 2016) are 5–10 years old; this is acceptable for a tiered evidence profile but should be noted as a corpus recency limitation.

Reviewer note

This rapid evidence synthesis on Sulforaphane NRF2 adopts an appropriately conservative, tiered framing and avoids broad causal or clinical claims in the conclusion. The search summary is explicit (12 databases, frozen protocol, documented admission funnel), which is a strength. The source bundle is reference-only but appears to match the cited author-year strings, and the bundle contains several human intervention studies (Brown 2015, Duran 2016, Doss 2016, Wise 2016, Mitra 2016) that are not adequately represented in the Evidence Landscape tables. The abstract's claim of 'no direct interventional hard-endpoint evidence' is technically defensible only if 'hard-endpoint' is narrowly defined to exclude bronchoprotection FEV1 changes, Nrf2 target gene expression, and safety/physiological response — a definition that should be made explicit. Several mechanistic and preclinical p-values are reported as 'significant source statistic' under a 'Strongest signal' header that risks being read as clinical efficacy. The limitations section is reasonably material (evidence-role imbalance, endpoint heterogeneity, numerics exclusion policy), and the gaps section identifies the right next steps but does not enumerate the 5 cross-study disagreements. Synthesis quality is adequate rather than strong because the outcome-class packets are descriptive lists without explicit cross-source integration, and the Key Findings section does not actually enumerate findings. The manuscript is salvageable with bounded edits focused on (1) reconciling the source_bundle with the Evidence Landscape tables, (2) correcting directness classification for the human intervention studies, (3) clarifying the 'Strongest signal' column definition, and (4) providing an actual Key Findings paragraph. Recommendation: revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis